Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBAT-ARF: Iloprost for Infectious Respiratory Failure
NCT06319274Phase 2Recruiting
- Start
- Apr 2024
- Primary completion
- Sep 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory failure (ARF) and endothelial dysfunction comparing Iloprost with Placebo (2 arms). Primary endpoint: 28-day all-cause mortality. Started Apr 2024; status: recruiting.
02
Drugs
iloprost
03
Conditions
acute respiratory failure (ARF)endothelial dysfunction
Beyond the preview
Go deeper on NCT06319274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06319274.